Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StreptAnova (University of Tennessee Health Science Center)
- Development stage
- Unknown
- Lead developer
- Vaxent
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
StreptAnova is a 30-valent recombinant protein subunit vaccine designed to prevent Group A streptococcal (GAS) infections, including pharyngitis, invasive disease, and rheumatic heart disease. Developed at the University of Tennessee Health Science Center by Dr. James B. Dale and commercialized by Vaxent and PREVENT, the vaccine was evaluated in a Phase I trial sponsored by Dalhousie University. The formulation consists of four recombinant proteins that incorporate N-terminal peptides from 30 different M protein serotypes of *Streptococcus pyogenes*, along with the Streptococcal protective antigen (Spa). Adjuvanted with aluminum hydroxide, StreptAnova is intended to provide broad-spectrum immunity against approximately 85% of GAS strains prevalent in North America and Europe. Phase I results indicated that the vaccine is safe, well-tolerated, and immunogenic in healthy adults.
- Brand names
- StreptAnova
- Other names
- 30-valent M protein-based vaccineGroup A streptococcal vaccineGAS vaccine
02
Targets
M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on StreptAnova (University of Tennessee Health Science Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StreptAnova (University of Tennessee Health Science Center).